JP7274223B2 - マイクロサテライト不安定性（ｍｓｉ）癌の予防及び治療のための共通腫瘍ネオアンチゲンをベースとした万能ワクチン - Google Patents

マイクロサテライト不安定性（ｍｓｉ）癌の予防及び治療のための共通腫瘍ネオアンチゲンをベースとした万能ワクチン Download PDF

Info

Publication number
JP7274223B2
JP7274223B2 JP2020501311A JP2020501311A JP7274223B2 JP 7274223 B2 JP7274223 B2 JP 7274223B2 JP 2020501311 A JP2020501311 A JP 2020501311A JP 2020501311 A JP2020501311 A JP 2020501311A JP 7274223 B2 JP7274223 B2 JP 7274223B2
Authority
JP
Japan
Prior art keywords
cancer
fsps
fsp
cvp
collection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020501311A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020532288A5 (enExample
JP2020532288A (ja
Inventor
ニコシア，アルフレド
スカルセッリ，エリーザ
レオーニ，グイド
ラーム，アルミン
Original Assignee
ノイスコム アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノイスコム アーゲー filed Critical ノイスコム アーゲー
Publication of JP2020532288A publication Critical patent/JP2020532288A/ja
Publication of JP2020532288A5 publication Critical patent/JP2020532288A5/ja
Application granted granted Critical
Publication of JP7274223B2 publication Critical patent/JP7274223B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020501311A 2017-07-12 2018-07-12 マイクロサテライト不安定性（ｍｓｉ）癌の予防及び治療のための共通腫瘍ネオアンチゲンをベースとした万能ワクチン Active JP7274223B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17181026.0 2017-07-12
EP17181026 2017-07-12
PCT/EP2018/069032 WO2019012082A1 (en) 2017-07-12 2018-07-12 UNIVERSAL VACCINE BASED ON SHARED TUMOR NEO-ANTIGENS FOR THE PREVENTION AND TREATMENT OF MICRO-SATELLITE INSTABILITY CANCER (MSI)

Publications (3)

Publication Number Publication Date
JP2020532288A JP2020532288A (ja) 2020-11-12
JP2020532288A5 JP2020532288A5 (enExample) 2021-08-05
JP7274223B2 true JP7274223B2 (ja) 2023-05-16

Family

ID=59366234

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020501311A Active JP7274223B2 (ja) 2017-07-12 2018-07-12 マイクロサテライト不安定性（ｍｓｉ）癌の予防及び治療のための共通腫瘍ネオアンチゲンをベースとした万能ワクチン

Country Status (19)

Country Link
US (1) US11578109B2 (enExample)
EP (1) EP3652606B1 (enExample)
JP (1) JP7274223B2 (enExample)
KR (1) KR102709778B1 (enExample)
CN (1) CN111328420B (enExample)
AU (1) AU2018298849B2 (enExample)
BR (1) BR112020000590A2 (enExample)
CA (1) CA3069047A1 (enExample)
DK (1) DK3652606T5 (enExample)
ES (1) ES2940087T3 (enExample)
FI (1) FI3652606T3 (enExample)
HU (1) HUE061840T2 (enExample)
IL (1) IL271966B2 (enExample)
MX (1) MX2020000413A (enExample)
NZ (1) NZ759940A (enExample)
PL (1) PL3652606T3 (enExample)
PT (1) PT3652606T (enExample)
SG (1) SG11202000250PA (enExample)
WO (1) WO2019012082A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3106573A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Cancer vaccines for colorectal cancer
WO2020022901A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Cancer vaccines for uterine cancer
WO2020022897A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database
CA3106567A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Cancer vaccines for kidney cancer
EP3827262A1 (en) 2018-07-26 2021-06-02 Frame Pharmaceuticals B.V. Cancer vaccines for breast cancer
CA3106574A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Arid1a, cdkn2a, kmt2b, kmt2d, tp53 and pten vaccines for cancer
TWI852977B (zh) * 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
WO2020163802A1 (en) * 2019-02-07 2020-08-13 Arizona Board Of Regents On Behalf Of Arizona State University Cancer specific frameshift vaccines
EP4061405A1 (en) 2019-11-18 2022-09-28 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
EP4149952A1 (en) * 2020-05-12 2023-03-22 Institut Curie Neoantigenic epitopes associated with sf3b1 mutations
WO2022009049A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
JP2024516542A (ja) * 2021-04-06 2024-04-16 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｍｈｃクラスｉペプチドを含む方法および組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017020026A1 (en) 2015-07-30 2017-02-02 Modernatx, Inc. Concatemeric peptide epitopes rnas

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922315A (en) 1997-01-24 1999-07-13 Genetic Therapy, Inc. Adenoviruses having altered hexon proteins
AU2003232485A1 (en) * 2002-04-18 2003-10-27 Mtm Laboratories Ag Neopeptides and methods useful for detection and treatment of cancer
WO2004092338A2 (en) * 2003-04-11 2004-10-28 Diadexus, Inc. Compositions, splice variants and methods relating to cancer specific genes and proteins
CN1824325A (zh) * 2005-12-16 2006-08-30 武汉大学 人乳头病毒dna嵌合疫苗及制备方法和应用
CA2915560A1 (en) * 2006-10-17 2008-04-24 Tomoaki Fujioka Peptide vaccines for cancers expressing mphosph1 or depdc1 polypeptides
TW201102081A (en) * 2009-05-11 2011-01-16 Oncotherapy Science Inc TTK peptides and vaccines including the same
NZ596603A (en) 2009-05-29 2013-07-26 Morphosys Ag A collection of antibodies or fragments having properties relevant to developability
JP2013523084A (ja) * 2010-04-09 2013-06-17 オンコセラピー・サイエンス株式会社 Ｃｄｃａ５ペプチドおよびそれを含むワクチン
DK2688907T3 (en) * 2011-03-24 2016-06-13 Inst Nat De La Sante Et De La Rech Medicale (Inserm) DOMINANT NEGATIVE HSP110 MUTANT AND ITS APPLICATION TO FORECAST AND treatment of cancers
US9458447B2 (en) * 2011-08-12 2016-10-04 Oncotherapy Science, Inc. MPHOSPH1 peptides and vaccines including the same
JP5890769B2 (ja) * 2012-12-13 2016-03-22 ループレヒト−カルルス・ウニヴェルジテート・ハイデルベルクＲｕｐｒｅｃｈｔ−Ｋａｒｌｓ−Ｕｎｉｖｅｒｓｉｔａｅｔ Ｈｅｉｄｅｌｂｅｒｇ がんの予防及び治療のためのｍｓｉ特異的なフレームシフトペプチド（ｆｓｐ）
RU2644677C2 (ru) * 2012-12-13 2018-02-13 Рупрехт-Карлс-Университэт Гейдельберг Мсн-специфичные пептиды со смещенной рамкой считывания (псрс) для предотвращения и лечения рака
US9205140B2 (en) * 2012-12-13 2015-12-08 Ruprecht-Karls-Universität MSI-specific frameshift peptides (FSP) for prevention and treatment of cancer
WO2014099979A2 (en) * 2012-12-17 2014-06-26 Virginia Tech Intellectual Properties, Inc. Methods and compositions for identifying global microsatellite instability and for characterizing informative microsatellite loci
WO2015112930A1 (en) * 2014-01-27 2015-07-30 Yale University Novel methods of identifying patients responsive to immunotherapeutic strategies
JP6913032B2 (ja) 2015-05-20 2021-08-04 ザ・ブロード・インスティテュート・インコーポレイテッド 共通ネオ抗原
CN106350578A (zh) * 2015-07-13 2017-01-25 中国人民解放军第二军医大学 Ny-eso-1在微卫星不稳定性肠癌的诊断和治疗中的应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017020026A1 (en) 2015-07-30 2017-02-02 Modernatx, Inc. Concatemeric peptide epitopes rnas

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Shen Luhui et al.，Abstract 469: Progress towards developing a universal, prophylactic cancer vaccine.，Cancer Res.，2013年04月，Vol.73, No.8 Suppl，p.1-4，https://cancerres.aacrjournals.org/content/73/8_Supplement/469，doi: 10.1158/1538-7445.AM2013-469
Stefan M. Woerner et al.，Systematic identification of genes with coding microsatellites mutated in DNA mismatch repair-deficient cancer cells.，Int. J. Cancer，2001年07月01日，Vol.93, No.1，p.12-19，doi: 10.1002/ijc.1299
Yvette Schwitalle et al.，Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells.，Cancer Immun.，2004年11月25日，Vol.4，p.14

Also Published As

Publication number Publication date
WO2019012082A1 (en) 2019-01-17
BR112020000590A2 (pt) 2020-07-14
AU2018298849B2 (en) 2022-07-14
US20200222519A1 (en) 2020-07-16
IL271966B2 (en) 2025-01-01
AU2018298849A1 (en) 2020-01-02
EP3652606A1 (en) 2020-05-20
IL271966A (en) 2020-02-27
PT3652606T (pt) 2023-03-16
SG11202000250PA (en) 2020-02-27
EP3652606B1 (en) 2023-01-11
CN111328420A (zh) 2020-06-23
HUE061840T2 (hu) 2023-08-28
ES2940087T3 (es) 2023-05-03
KR102709778B1 (ko) 2024-09-26
US11578109B2 (en) 2023-02-14
FI3652606T3 (fi) 2023-03-16
RU2019144505A3 (enExample) 2021-08-12
WO2019012082A9 (en) 2019-05-02
DK3652606T3 (da) 2023-03-13
IL271966B1 (en) 2024-09-01
RU2019144505A (ru) 2021-08-12
KR20200029443A (ko) 2020-03-18
PL3652606T3 (pl) 2023-04-24
DK3652606T5 (da) 2024-08-26
NZ759940A (en) 2023-07-28
CN111328420B (zh) 2023-07-25
JP2020532288A (ja) 2020-11-12
MX2020000413A (es) 2020-09-28
CA3069047A1 (en) 2019-01-17

Similar Documents

Publication Publication Date Title
CN111328420B (zh) 用于预防和治疗微卫星不稳定(msi)癌症的基于共有肿瘤新抗原的通用疫苗
AU2021232660B2 (en) HPV vaccines
JP7551495B2 (ja) Ｈｐｖワクチン
RU2019119272A (ru) Вирусная доставка неоантигенов
JP2020530761A (ja) 非ヒト大型類人猿アデノウイルスの核酸配列及びアミノ酸配列、それを含有するベクター、並びにその使用
JP2024059879A (ja) 硬骨魚類インバリアント鎖癌ワクチン
CN111670046A (zh) 疫苗的t细胞增强剂
JP2026082958A (ja) ゴリラ・アデノウイルスの核酸配列およびアミノ酸配列、それを含むベクター、およびそれらの使用
CN112512568A (zh) 遗传修饰的重组痘苗安卡拉(rmva)疫苗改善的稳定性及其制备方法
KR20200100686A (ko) B형 간염 면역화 레지멘 및 조성물
NZ543922A (en) Synthetic gene encoding human carcinoembryonic antigen and uses thereof
HK40029760B (en) A universal vaccine based on shared tumor neoantigens for prevention and treatment of micro satellite instable (msi) cancers
HK40029760A (en) A universal vaccine based on shared tumor neoantigens for prevention and treatment of micro satellite instable (msi) cancers
RU2808567C2 (ru) Противораковая вакцина с инвариантной цепью из костистых рыб
CN121627808A (zh) Hpv-52型e6蛋白的特异性ctl表位肽及其应用
NZ759892B2 (en) Non human great apes adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210617

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210617

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220927

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230125

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230404

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230424

R150 Certificate of patent or registration of utility model

Ref document number: 7274223

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250